Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge?Based Immunoassays for European Clinical Laboratories
Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge?Based Immunoassays for European Clinical Laboratories
Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative
Bio-Techne?Launches Simple?Plex?Ultra-Sensitive?Assays on Ella?Platform to Enable?Femtogram-Level?Detection of Neurological Biomarkers
Bio-Techne to Host Conference Call on February 4, 2026, to Announce Second Quarter Fiscal 2026 Financial Results
Quebec Innovative Materials Corp. Announces U.S. Affiliate Orvian Receives Minnesota DNR Registration for Exploratory Boring
